Genome patent fight erupts.

@article{Roberts1991GenomePF,
  title={Genome patent fight erupts.},
  author={Leslie Roberts},
  journal={Science},
  year={1991},
  volume={254 5029},
  pages={
          184-6
        }
}
  • L. Roberts
  • Published 11 October 1991
  • Biology, Medicine
  • Science
At a Congressional briefing while describing a new project to sequence partially every gene active in the human brain, it was made known that the National Institutes of Health was planning to file patent applications on 1,000 of these sequences a month. The scheme has engendered a firestorm of criticism from genome scientists and project officials alike. The critics argue that these sequences probably can't be patented in the first place - and even if they can, they shouldn't be. The plan would… Expand
Patenting cDNA 1993: Efforts and happenings
TLDR
The United States Patent Trademark Office (US PTO) strongly rejected the NIH's application for patents for the sequences of cDNA fragments from a brain library, and the NIH is appealing the decision. Expand
Patents on random complementary DNA fragments?
TLDR
The proposal by the National Institutes of Health to patent products resulting merely from sequencing the human genome is a mistake; it relies on deficiencies in law concerning what is "useful" as a requirement for patents. Expand
Patents, Morality and DNA: Should there be Intellectual Property Protection of the Human Genome Project?
TLDR
The appropriateness of using existing patent laws in various jurisdictions in an effort to secure protection of the work currently being carried out on the Human Genome Project is examined. Expand
Lawyers' delights and geneticists' nightmares: at forty, the double helix shows some wrinkles.
TLDR
It is proposed that legal protection be considered only for those RNA/DNA sequences, either natural or artificial, which can generate practical applications per se, and not through their expression products. Expand
MRC denies blocking access to genome data.
TLDR
The specific issue here is what both NIH and the MRC plan to do with the data emerging from their efforts to find all the active genes in the human genome, which are estimated to number 100,000. Expand
Patents in genomics and human genetics.
TLDR
Whole-genome sequencing will confront uncertainty about infringing granted patents, but jurisprudence trends away from upholding the broadest and potentially most troublesome patent claims. Expand
Costs and Benefits of Genomics Patents
  • Jonathan D. Putnam
  • Medicine
  • American journal of pharmacogenomics : genomics-related research in drug development and clinical practice
  • 2004
TLDR
The onus appears to lie on the critics to create a model with the desirable properties of the patent system, but with fewer of its acknowledged weaknesses, such as ‘monopoly’ pricing and ‘patent thickets’. Expand
Patentability of human genes: the conceptual differences between the industrialised and Latin American countries
  • S. Bergel
  • Computer Science, Medicine
  • Journal of Community Genetics
  • 2015
TLDR
The recent decision of the Supreme Court in the Myriad case is part of a pro-patent movement, even when its superficial reading seems to be oriented in the opposite direction. Expand
Gene ownership versus access: Meeting the needs
Two developments, which simultaneously and independently occurred in the 1980s, have substantially impacted the way drugs are currently being discovered and developed. First, there was a significantExpand
The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project
TLDR
The Bermuda Principles for DNA sequence data sharing endured as an archetype for how rapid data sharing could be realized and rationalized, and permitted adaptation to the needs of various scientific communities. Expand
...
1
2
3
4
...

References

Gambling on a shortcut to genome sequencing
TLDR
Craig Venter of the National Institute of Neurological Disorders and Stroke says that focusing on the expressed genes may be even more useful than expected, and his strategy involves randomly selecting clones from cDNA libraries which theoretically contain all the genes that are switched on at a particular time in a particular tissue. Expand